GeneCentric launches with UNC licenses
October 2012

DURHAM, N.C.óGeneCentric announced at the end of August two exclusive licenses to diagnostic platform technologies from the University of North Carolina at Chapel Hill (UNC-Chapel Hill). GeneCentric has in-licensed the Lung Subtype Platform from UNC-Chapel Hill, technology that can determine several subtypes of lung cancer based on genetic fingerprints from tumor samples. The second licensing agreement grants GeneCentric exclusive worldwide commercial rights to a 13-gene vascular endothelial growth factor signature that is associated with distant metastases as well as poor outcomes. Financial details were not disclosed.
"The next era of cancer clinical trials and, in fact, cancer care will be driven by a tumor's molecular signature," Shelley Earp, director of UNC Lineberger Comprehensive Cancer Center, said in a press release regarding the license agreements.

1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.